ABBVNYSEHealthcare

ABBVIE INC

Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.

Latest price

$291.31

+1.07%

Alpha Vantage · 11/6/2026

Industry: Drug Manufacturers - GeneralCategory: Domestic Common StockCurrency: USDNews: 1 recent

Analyze ABBV free

One-year price history

Adjusted daily closes · 252 observations · as of Nov 6, 2026

Historical data, not a forecast

1 month

+7.6%

3 months

+18.2%

6 months

+46.5%

1 year

+37.0%

Year to date

+31.3%

52-week range

$194.80 – $294.89

Fundamental snapshot

Latest reported period: Sep 30, 2026

Sharadar reported data

Market cap

$514.92B

P/E

49.8

P/B

-111.3

P/S

7.8

Revenue

$66.01B

Net income

$10.34B

Diluted EPS

5.81

Gross margin

73.70%

Net margin

15.70%

Return on equity

-201.00%

Total debt

$80.9B

Cash

$10.77B

Free cash flow

$18.87B

Latest eight reported quarters

Reported quarterly values, newest first

Period	Revenue	Net income	Gross margin	Net margin	Free cash flow
Sep 30, 2026	$17.4B	$4.22B	75.40%	24.20%	$7.31B
Jun 30, 2026	$16.99B	$3.61B	74.70%	21.30%	$3.11B
Mar 31, 2026	$15B	$695M	71.90%	4.60%	$3.56B
Dec 31, 2025	$16.62B	$1.82B	72.60%	10.90%	$4.89B
Sep 30, 2025	$15.78B	$186M	66.40%	1.20%	$6.64B
Jun 30, 2025	$15.42B	$938M	71.80%	6.10%	$4.88B
Mar 31, 2025	$13.34B	$1.29B	70.00%	9.60%	$1.4B
Dec 31, 2024	$15.1B	-$22M	70.90%	-0.10%	$6.76B

Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.

Recent ABBV news

All market news

Simply Wall St·Nov 4, 202674 signal

How Investors May Respond To Regeneron Pharmaceuticals (REGN) Earnings Beat

Regeneron Pharmaceuticals reported strong third-quarter 2026 results with US$5.1 billion in revenue and US$1.95 billion in net income, exceeding expectations. The company also affirmed its quarterly dividend and continued share buybacks, while expanding its BARDA agreement for Ebola treatment and presenting positive data for Libtayo in skin cancer. These results reinforce Regeneron's earnings engine, with a focus on late-stage pipeline execution and competition in eye care, and analysts anticipate continued revenue and earnings growth through 2029.

Original source